Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.

Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes phenotyped for S-mephenytoin 4'-hydroxylation in vitro and 11 recombinant human CYP isoforms. Individual Eadie-Hoffstee plots for IMI N-demethylation and 2-hydroxylation showed a monophasic profile in microsomes obtained from three putative S-mephenytoin poor metabolizer (PM) livers, whereas the plots gave a biphasic relationship (except for one case in 2-hydroxylation) in those from the three extensive metabolizer (EM) livers. Effects of CYP-selective inhibitor/substrate probes on the two metabolic reactions were examined at the two IMI concentrations (2 and 400 microM) with microsomes obtained from the two PM and three EM livers. S-mephenytoin inhibited IMI N-demethylation by 50% at the low concentration in microsomes from the EM livers with no discernible effect on this pathway in those from the PM livers. Furafylline inhibited the N-demethylation by about 60% at the low and high substrate concentrations in microsomes from both the EM and PM livers. Quinidine abolished the 2-hydroxylation at the low and high concentrations in microsomes from both the EM and the PM livers. Among the recombinant human CYPs, CYP2C19, 2C18, 2D6, 1A2, 3A4 and 2B6 in rank order catalyzed the N-demethylation, whereas CYP2D6, 2C19, 1A2, 2C18 and 3A4 catalyzed the 2-hydroxylation. The Km values obtained from recombinant CYP2C19 and 1A2 approximated those of the high- and low-affinity components from human liver microsomes for IMI N-demethylation, respectively. For IMI 2-hydroxylation, the respective Km values obtained from recombinant CYP2D6 and 2C19 were close to those of the high- and low-affinity components from human liver microsomes. Our human liver microsomal study using the near-therapeutic IMI concentration (2 microM) suggests that 1) CYP2C19 and 1A2 are involved in the N-demethylation and the 2-hydroxylation is mediated exclusively by CYP2D6 and partially by CYP2C19 in the EM livers, and 2) CYP1A2 and 2D6 play a major role in IMI N-demethylation and 2-hydroxylation, respectively, in the PM livers. Our recombinant human CYP isoform study, in general, supports this conclusion.

[1]  K. Chiba,et al.  Simultaneous High‐Performance Liquid Chromatography‐Electrochemical Detection Determination of Imipramine, Desipramine, Their 2‐Hydroxylated Metabolites, and Imipramine N‐Oxide in Human Plasma and Urine: Preliminary Application to Oxidation Pharmacogenetics , 1993, Therapeutic Drug Monitoring.

[2]  T Sakaki,et al.  Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. , 1996, Biochemical pharmacology.

[3]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[4]  E. Skjelbo,et al.  Inhibitors of imipramine metabolism by human liver microsomes. , 1992, British journal of clinical pharmacology.

[5]  S. Otton,et al.  Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype , 1986, Clinical pharmacology and therapeutics.

[6]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[7]  P. Beaune,et al.  Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. , 1993, Molecular pharmacology.

[8]  R. Kato,et al.  Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P‐450 human‐2 , 1990, Clinical pharmacology and therapeutics.

[9]  R. Eilers,et al.  Therapeutic Drug Monitoring for the Treatment of Psychiatric Disorders , 1995, Clinical pharmacokinetics.

[10]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[11]  S. Wrighton,et al.  Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.

[12]  A. Boobis,et al.  The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. , 1989, Biochemical pharmacology.

[13]  U. Meyer,et al.  Role of P450IID6, the target of the sparteine‐debrisoquin oxidation polymorphism, in the metabolism of imipramine , 1991, Clinical pharmacology and therapeutics.

[14]  R. Branch,et al.  Genetic polymorphism of S-mephenytoin hydroxylation. , 1989, Pharmacology & therapeutics.

[15]  B. Mellström,et al.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes , 1984, Clinical pharmacology and therapeutics.

[16]  K. Chiba,et al.  The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. , 1994, British journal of clinical pharmacology.

[17]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[18]  K. Brøsen,et al.  First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.

[19]  P. Bech,et al.  Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics , 2004, European Journal of Clinical Pharmacology.

[20]  K. Chiba,et al.  The kinetic characterization of S-mephenytoin 4-hydroxylase (P-450IICMP) activity in human liver samples obtained as surgical waste from Japanese patients. , 1993, Drug Metabolism And Disposition.

[21]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[22]  J. Hallas,et al.  The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine , 1991, Clinical pharmacology and therapeutics.

[23]  S. Preskorn,et al.  Therapeutic drug monitoring. Principles and practice. , 1993, The Psychiatric clinics of North America.

[24]  L. Bertilsson,et al.  Genetically variable metabolism of antidepressants and neuroleptic drugs in man. , 1993, Pharmacogenetics.

[25]  T. Ishizaki,et al.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.

[26]  R. Kato,et al.  Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. , 1993, Pharmacogenetics.

[27]  S. Kitareewan,et al.  Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. , 1994, Biochemistry.

[28]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[29]  S. Ohmori,et al.  Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. , 1993, Biological & pharmaceutical bulletin.

[30]  W. Trager,et al.  Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. , 1993, Chemical research in toxicology.

[31]  R. Tukey,et al.  Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. , 1993, The Journal of pharmacology and experimental therapeutics.

[32]  J. Miners,et al.  Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. , 1994, British journal of clinical pharmacology.

[33]  A. D. Rodrigues,et al.  Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.

[34]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[35]  P. Watkins,et al.  Identification of an inducible form of cytochrome P-450 in human liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[36]  K. Chiba,et al.  Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. , 1994, The Journal of pharmacology and experimental therapeutics.

[37]  F. Sallee,et al.  Clinical Pharmacokinetics of Imipramine and Desipramine , 1990, Clinical pharmacokinetics.

[38]  H. Akaike.  A new look at the statistical model identification , 1974 .

[39]  D. Greenblatt,et al.  N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. , 1995, The Journal of pharmacology and experimental therapeutics.

[40]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[41]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[42]  K. Chiba,et al.  Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. , 1996, Journal of clinical psychopharmacology.

[43]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[44]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.